Vericel : Presentation May 2025

Published: 2025-05-27 00:12:04 ET VCEL

Published on 05/27/2025 at 00:12

CORPORATE PRESENTATION

MAY 2025

Vericel is a Leader in Advanced Therapies in Sports Medicine and

Our Vision

Every patient benefits from therapies as unique as they are

Burn Care, Combining Innovations in Biology with Medical Technologies

SPORTS MEDICINE SEVERE BURNS

Our Mission

We provide precision therapies that repair injuries and restore lives

PORTFOLIO OF INNOVATIVE CELL THERAPIES AND SPECIALTY BIOLOGICS WITH SIGNIFICANT BARRIERS TO ENTRY

3

Vericel is Well-Positioned to Deliver Sustained Long-Term Growth

High revenue growth profile

Sustained positive adjusted EBITDA and Operating Cash Flow

GAAP Net Income positive in 2024

~$162M in Cash & Investments

❶

Strong Financial Profile

❷ High-Growth

Market leader in knee cartilage repair

20% growth in 2023 and 2024

o

MACI Arthr launched in Q3 2024

Continued strong growth in MACI surgeons and biopsies

e

On track to initiate MACI Ankl MASCOT clinical study in H2 2025

➍

❸

Second High-Growth Franchise in Burn Care

Launched in the U.S. in Q4 2023; Pediatric indication in Q3 2024

Potentially life-saving product with large market opportunity

Expanding Core Portfolio

New manufacturing facility provides flexibility for potential MACI OUS expansion

4

Large Underpenetrated Markets with Total Addressable Market Opportunity Expanding to Over $5 Billion in the Years Ahead

+ $1 Billion

~$5 Billion TAM

~$4 Billion

TAM

NexoBrid launched in 2023

MACI Arthro launched in 2024; targets largest segment of current MACI addressable market

Anticipate initiating MACI Ankle study in 2025

$3 Billion+

$5 Billion

$600 Million

$600 Million

5

Disclaimer

Vericel Corporation published this content on May 27, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 27, 2025 at 04:11 UTC.